The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • CardieX (CDX) was up more than 30 per cent this morning after expanding two clinical trials with existing customers
  • The company’s subsidiary, ATCOR Medical, will expand the existing contracts with AstraZeneca and Bayer for the supply of the XCEL device
  • XCEL measures the central blood pressure in adult patients
  • The extended contracts have added more than $918,000 in contract value
  • Company shares have dropped slightly however, they are still 12.5 per cent in the green and trading for 1.8 cents each

CardieX (CDX) was up more than 30 per cent this morning after expanding two clinical trials with existing customers.

The company’s subsidiary, ATCOR Medical, will expand the existing contracts with AstraZeneca and Bayer for the supply of the XCEL device.

ATCOR will also provide data management services for the full period of the trial.

The XCEL device is the only FDA (Food and Drug Administration) cleared device for measuring central blood pressure in adult patients.

It uses traditional blood pressure cuffs to measure blood pressure but it also maps the shape of the pulse waveform in the upper arm.

The device is used by clinicians, research institutions and pharmaceutical companies to monitor critical hemodynamic data (blood flow) during patient treatment and drug trials in multiple clinical settings and multiple disease states.

AstraZeneca originally contracted ATCOR in October 2018 to provide clinical services and devices with a contract value worth US$226,000 (AUD$359,995).

The total value of this contract has now been increased to US$340,217 (AUD$541,932).

Bayer contracted ATCOR in December 2017 to provide clinical services and devices with a contract value of US$756,000 (AUD$1.2 million).

This contract has now been extended to US$1.261 million (AUD$2 million).

In addition to these contracts, CardieX is expecting further changes in additional existing trials as well as new trial contracts in the immediate future.

This will add significant new incremental revenue for CardieX in 2020.

Company shares have dropped slightly however, they are still 12.5 per cent in the green and trading for 1.8 cents each at 11:29 am AEDT.

CDX by the numbers
More From The Market Online

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…

Little Green Pharma heading into Q2 cashed up after record sales

Little Green Pharma (ASX:LGP) wound up Q1CY24 with $5M in cash after posting record sales of…

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…